Latest court orders, judgments, and legal developments from Indian courts — AI-curated and summarized.
The Bombay High Court in Ashit Padhaya v. Assistant Controller of Patents emphasized that Controllers must base patent revocations on disclosed evidence, as fresh undisclosed evidence cannot be considered. This marks a significant procedural clarification.
The Bombay High Court in Ashit Padhaya v. Assistant Controller of Patents stressed the necessity for Controllers to disclose all evidence considered to parties involved in post-grant opposition proceedings. This enforcement of procedural transparency aligns with the principles of fairness in patent adjudications.
In the case of Array Biopharma Inc. v. Deputy Controller of Patents, the Delhi High Court reiterated that patent objections must be substantiated with evidence rather than being mere assertions. The ruling underscored the importance of claim-specific details when assessing inventive steps under Sections 3(d) and 3(i) of the Patents Act.
The Bombay High Court emphasized procedural fairness in patent opposition cases, ruling that patent revocation based on undisclosed evidence undermines the rights of patentees and opposition boards. This decision underscores the necessity for transparency in the evidentiary process during patent assessments.
In Intra Cellular Therapies v. Controller of Patents, the Delhi High Court examined critical issues related to disclosure and therapeutic efficacy standards under Indian patent law, impacting pharmaceutical patent evaluations.
The Bombay High Court ruled on the procedural responsibilities of Controllers in patent assessments, particularly regarding their reliance on undisclosed evidence during post-grant opposition proceedings. This case highlights the importance of transparency in the patent evaluation process.
The article discusses India's ongoing intermediate liability framework and the recent challenges posed by copyright enforcement. The Delhi High Court has sought clarity on these matters from Meta, marking a pivotal moment in digital copyright law.
The Delhi High Court has addressed critical aspects of pharmaceutical patent law in the case of Intra Cellular Therapies v. Controller of Patents, revisiting coverage disclosure and the therapeutic efficacy threshold under Section 3(d).
The Delhi High Court's ruling in Saregama v. Ilaiyaraaja clarifies the evidentiary threshold necessary to support interim injunctions in copyright disputes, addressing assignment validity and digital rights issues.
The Delhi High Court's decision in Home Box Office Inc. v. Streamzy.To addresses the balance between combating online piracy and the limitations of website blocking under Section 79 of the IT Act. The ruling seeks to define the role of intermediaries more clearly.
The Delhi High Court's decision in Saregama v. Ilaiyaraaja has shed light on the evidentiary threshold for establishing copyright ownership in interim injunction applications. The ruling addresses the balance between evidence required and potential irreparable injury.
The Delhi High Court addressed key issues in pharmaceutical patent law regarding coverage disclosure and therapeutic efficacy requirements under Section 3(d) in Intra Cellular Therapies v. Controller of Patents. The ruling highlights complexities in how patent claims are assessed in India.